nf-kb

NF-κB (Nuclear Factor Kappa B)

Introduction

Nf Κb (Nuclear Factor Kappa B) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

NF-κB[@mattson2001] (nuclear factor kappa-light-chain-enhancer of activated B cells) is a family of transcription factors that plays central roles in inflammation, immune responses, cell survival, and [synaptic plasticity](/mechanisms/synaptic-plasticity). In the central nervous system, NF-κB[@mattson2001] is activated in [neurons](/entities/neurons), [astrocytes](/cell-types/astrocytes), and [microglia](/cell-types/microglia), where it serves as a critical mediator linking [neuroinflammation](/mechanisms/neuroinflammation) to neuronal death in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), and [Huntington's disease](/mechanisms/huntington-pathway) ([Mattson & Camandola, 2001](https://doi.org/10.1172/JCI11916); [Singh & Singh, 2020](https://pubmed.ncbi.nlm.nih.gov/31823227/)). [@hayden2008]

...

NF-κB (Nuclear Factor Kappa B)

Introduction

Nf Κb (Nuclear Factor Kappa B) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

NF-κB[@mattson2001] (nuclear factor kappa-light-chain-enhancer of activated B cells) is a family of transcription factors that plays central roles in inflammation, immune responses, cell survival, and [synaptic plasticity](/mechanisms/synaptic-plasticity). In the central nervous system, NF-κB[@mattson2001] is activated in [neurons](/entities/neurons), [astrocytes](/cell-types/astrocytes), and [microglia](/cell-types/microglia), where it serves as a critical mediator linking [neuroinflammation](/mechanisms/neuroinflammation) to neuronal death in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), and [Huntington's disease](/mechanisms/huntington-pathway) ([Mattson & Camandola, 2001](https://doi.org/10.1172/JCI11916); [Singh & Singh, 2020](https://pubmed.ncbi.nlm.nih.gov/31823227/)). [@hayden2008]

NF-κB occupies a paradoxical position in neurodegeneration: in [neurons](/entities/neurons), it is generally neuroprotective, promoting survival through anti-apoptotic gene expression, while in [microglia](/cell-types/microglia) and [astrocytes](/cell-types/astrocytes), it drives pro-inflammatory cascades that exacerbate neuronal damage [(Jha et al., 2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11545113/). This dual nature makes NF-κB both a compelling and a challenging therapeutic target.

Molecular Biology

Protein Family

The NF-κB[@mattson2001] family consists of five related proteins that form homo- and heterodimers with distinct DNA-binding specificities and transcriptional targets ([Hayden & Ghosh, 2008](https://doi.org/10.1016/j.cell.2008.01.020)): [@ju2022]

| Subunit | Gene | Precursor | Key Features | [@jha2024]
|---------|------|-----------|--------------| [@lian2024]
| p65 (RelA) | RELA | — | Contains transactivation domain; most abundant subunit in CNS | [@snow2021]
| RelB | RELB | — | Induces distinct transcriptional programs via non-canonical pathway | [@singh2020]
| c-Rel | REL | — | Important for lymphocyte function; expressed in [neurons](/entities/neurons) | [@thakur2023]
| p50 (NF-κB[@mattson2001]1) | NFKB1 | p105 | Processed from p105 precursor; lacks transactivation domain | [@shi2025]
| p52 (NF-κB[@mattson2001]2) | NFKB2 | p100 | Processed from p100; active in non-canonical signaling | [@bido2024]

The p65/p50 heterodimer is the most common transcriptionally active form in the brain and is the primary mediator of inflammatory gene expression in [microglia](/cell-types/microglia) and [astrocytes](/cell-types/astrocytes) ([Karin & Ben-Neriah, 2000](https://doi.org/10.1146/annurev.immunol.18.1.621)). [@gupta2023]

Canonical (Classical) Pathway

The canonical NF-κB[@mattson2001] pathway is the primary signaling route in neuroinflammation[@karin2000] ([Hayden & Ghosh, 2008](https://doi.org/10.1016/j.cell.2008.01.020)): [@sun2011]

Stimulus recognition: Pro-inflammatory cytokines (TNF-α, IL-1β), pathogen-associated molecular patterns (via [TLR4](/entities/tlr4), or damage-associated molecular patterns (including [amyloid-beta](/proteins/amyloid-beta) aggregates) activate upstream receptors.

IKK complex activation: The IκB kinase (IKK) complex — consisting of IKKα, IKKβ, and the regulatory subunit NEMO (IKKγ) — is activated.

IκB phosphorylation and degradation: IKKβ phosphorylates IκBα, marking it for K48-linked ubiquitination and proteasomal degradation.

Nuclear translocation: Freed NF-κB[@mattson2001] dimers (typically p65/p50) translocate to the nucleus.

Transcriptional activation: NF-κB[@mattson2001] binds κB motifs in target gene promoters, inducing expression of cytokines, chemokines, complement components, and pro-survival genes.

This pathway mediates rapid, transient responses and is the primary driver of microglial inflammatory activation. [@astrocytes]

Non-Canonical (Alternative) Pathway

The non-canonical pathway involves NF-κB[@mattson2001]-inducing kinase (NIK) and IKKα-mediated processing of p100 to p52, which pairs with RelB. This pathway produces slower, sustained responses and is particularly important for lymph node development and adaptive immune regulation. In the CNS, the non-canonical pathway contributes to [astrocyte](/cell-types/astrocytes) activation and synaptic maintenance ([Sun, 2011](https://doi.org/10.1038/cdd.2011.71)). [@microgliacelltypesmicroglia]

Functions in the Central Nervous System

Neuronal NF-κB[@mattson2001]: Neuroprotection and Synaptic Plasticity

In [neurons](/entities/neurons), NF-κB[@mattson2001] is constitutively active at low levels and serves primarily protective functions ([Mattson, 2005](https://doi.org/10.1385/MN:31:1-3:175)): [@trem]

Synaptic plasticity and memory: [@tau]

• NF-κB[@mattson2001] is rapidly activated in hippocampal [neurons](/entities/neurons) during [long-term potentiation](/mechanisms/long-term-potentiation) ([LTP](/mechanisms/long-term-potentiation) and is required for memory consolidation ([Albensi & Mattson, 2000](https://doi.org/10.1002/(SICI)1098-2396(200002)35:2<151::AID-SYN8>3.0.CO;2-P))
• Controls expression of synaptic scaffolding proteins (PSD-95, SAP97) and [NMDA receptor](/entities/nmda-receptor)] receptor] subunit NR2B
• Regulates [BDNF](/proteins/bdnf-protein) transcription, linking activity to trophic support
• Required for late-phase [LTP](/mechanisms/long-term-potentiation) and long-term memory formation

Neuronal survival: [@nfkb]

• Drives expression of anti-apoptotic genes (Bcl-2, Bcl-xL, IAPs, Mn-SOD)
• Protects against excitotoxic injury by buffering calcium responses
• Mediates neurotrophic factor signaling downstream of [BDNF](/proteins/bdnf-protein) and [GDNF](/entities/gdnf)
• Supports DNA repair mechanisms via Ku70/Ku80 expression

Glial NF-κB[@mattson2001]: neuroinflammation Driver

In contrast to its protective neuronal role, glial NF-κB [@mattson2001] activation is a central driver of neurotoxic [neuroinflammation](/mechanisms/neuroinflammation) [@karin2000]: [@nfkba]

Microglial activation ([Snow & Albensi, 2021](https://doi.org/10.3233/JAD-210111)): [@nfkbb]

• Canonical NF-κB [@mattson2001] activation in [microglia](/cell-types/microglia) drives transcription of TNF-α, IL-1β, IL-6, and iNOS
• Cooperates with [NLRP3](/mechanisms/nlrp3-inflammasome) inflammasome activation to promote IL-1β and IL-18 release
• Promotes transition to [disease-associated [microglia](/entities/microglia) (DAM) phenotype
• Induces expression of [BACE1](/proteins/bace1-protein), promoting amyloidogenic [APP](/proteins/amyloid-beta-protein) processing

Astrocyte activation ([Lian et al., 2024](https://doi.org/10.1038/s41598-024-65248-1)): [@nfkbc]

• Astrocytic NF-κB[@mattson2001] promotes reactive [astrogliosis](/cell-types/astrocytes) and loss of neurotrophic support
• Drives production of complement component C3, which mediates synapse elimination
• Reduces glutamate transporter expression, contributing to [excitotoxicity](/entities/excitotoxicity)
• NF-κB[@mattson2001]-dependent astrocytic activation leads to [Aβ42](/proteins/amyloid-beta) accumulation and iNOS generation

Role in Alzheimer's Disease

Chronic NF-κB[@mattson2001] Activation in AD Brain

NF-κB[@mattson2001] is chronically hyperactivated in [Alzheimer's disease](/diseases/alzheimers-disease) brain tissue, particularly in vulnerable regions including the [hippocampus](/brain-regions/hippocampus) and [entorhinal [cortex](/brain-regions/cortex) ([Singh et al., 2022](https://doi.org/10.1016/j.nbd.2022.105642)):

• [neurons](/entities/neurons): Increased nuclear p65 in degenerating [neurons](/entities/neurons) adjacent to amyloid plaques
• [microglia](/cell-types/microglia): Sustained NF-κB[@mattson2001] activation in plaque-associated [microglia](/cell-types/microglia)
• [astrocytes](/cell-types/astrocytes): Elevated NF-κB[@mattson2001] activity in reactive [astrocytes](/cell-types/astrocytes) surrounding plaques

Amyloid–NF-κB[@mattson2001] Feed-Forward Loop

NF-κB[@mattson2001] participates in a destructive feed-forward loop with [amyloid-beta](/proteins/amyloid-beta) ([Ju Hwang et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36012242/)):

[Aβ](/proteins/amyloid-beta-protein) oligomers] activate microglial [TLR4](/entities/tlr4) and [RAGE](/proteins/rage) receptors, triggering NF-κB[@mattson2001]

NF-κB[@mattson2001] upregulates [BACE1 expression, increasing amyloidogenic processing of [APP](/entities/app-protein)

NF-κB[@mattson2001]-driven pro-inflammatory cytokines further activate [BACE1 and [γ-secretase](/entities/gamma-secretase)

More [Aβ](/proteins/amyloid-beta-protein) is produced, perpetuating the inflammatory cycle

[Aβ](/proteins/amyloid-beta-protein)-induced [ROS](/mechanisms/oxidative-stress) further amplify NF-κB[@mattson2001] activation via redox-sensitive IKK

NF-κB[@mattson2001] and Tau Pathology

NF-κB[@mattson2001] also links to tau] hyperphosphorylation]:

• NF-κB[@mattson2001] activation upregulates the phosphatase inhibitor SET/I2PP2A, reducing [PP2A](/entities/pp2a) activity
• Decreased [PP2A](/entities/pp2a) activity leads to hyperphosphorylation of tau] at disease-relevant epitopes
• Glycated tau] triggers [ROS](/mechanisms/oxidative-stress) production, further activating NF-κB[@mattson2001]
• NF-κB[@mattson2001]-dependent [GSK-3β](/entities/gsk-3-beta) and [CDK5](/proteins/cdk5) activation promotes tau] kinase activity

Role in Parkinson's Disease

NF-κB[@mattson2001] plays a significant role in [dopaminergic neurodDegeneration](/mechanisms/dopaminergic-neurodegeneration) in [Parkinson's disease](/diseases/parkinsons-disease) ([Singh & Singh, 2020](https://pubmed.ncbi.nlm.nih.gov/31823227/)):

• Immunohistochemical analyses of PD brain sections reveal a 70-fold increase in the proportion of [dopaminergic neurons](/cell-types/dopaminergic-neurons-snpc) in the [substantia nigra](/brain-regions/substantia-nigra) exhibiting nuclear p65 immunoreactivity compared to age-matched controls
• [Alpha-synuclein](/proteins/alpha-synuclein) oligomers potentiate neuroinflammatory NF-κB [@mattson2001] signaling in [microglia](/cell-types/microglia), amplifying dopaminergic neuron damage ([Bido et al., 2024](https://doi.org/10.1186/s40035-024-00401-4))
• NF-κB[@mattson2001]-driven microglial activation is an early event in PD pathogenesis, preceding overt neuronal loss
• [LRRK2/proteins/lrrk2 mutations enhance NF-κB[@mattson2001] signaling, linking genetic risk to inflammatory mechanisms

Role in ALS and Huntington's Disease

[ALS](/diseases/amyotrophic-lateral-sclerosis): Spinal cords of ALS patients show increased NF-κB[@mattson2001] activation in [astrocytes](/cell-types/astrocytes) associated with degenerating [motor neurons](/cell-types/motor-neurons). Mutant [SOD1/proteins/sod1-mediated NF-κB[@mattson2001] activation in glia contributes to non-cell-autonomous motor neuron toxicity ([Mattson & Camandola, 2001](https://doi.org/10.1172/JCI11916)).

[Huntington's disease](/mechanisms/huntington-pathway): In contrast to its deleterious role in AD and PD glia, neuronal NF-κB[@mattson2001] appears protective in HD. Mice lacking the p50 subunit (NF-κB[@mattson2001]1 knockout) exhibit increased striatal neuron damage and enhanced motor dysfunction after mitochondrial toxin exposure, indicating that NF-κB[@mattson2001] activation serves a neuroprotective function in [medium spiny neurons](/cell-types/medium-spiny-neurons) ([Mattson & Camandola, 2001](https://doi.org/10.1172/JCI11916)).

Therapeutic Targeting

The Dual-Role Challenge

The opposing functions of NF-κB[@mattson2001] in [neurons](/entities/neurons) (protective) versus glia (inflammatory) make therapeutic targeting extremely challenging ([Jha et al., 2024](https://pmc.ncbi.nlm.nih.gov/articles/PMC11545113/)):

• When neuronal NF-κB[@mattson2001] is inhibited, pro-apoptotic signaling via [caspase-8](/proteins/caspase-8) predominates, accelerating neuronal death
• Global NF-κB[@mattson2001] inhibition can impair immune defense and worsen outcomes
• Cell-type-specific targeting is needed but technically difficult

Pharmacological Approaches

Direct NF-κB[@mattson2001] inhibitors ([Thakur et al., 2023](https://doi.org/10.3390/biomedicines11092587)):

• IKK inhibitors: BAY 11-7082, IMD-0354, BMS-345541 — block IκB phosphorylation
• Proteasome inhibitors: Bortezomib — prevents IκB degradation (limited CNS penetration)
• Decoy oligonucleotides: κB-motif decoys sequester NF-κB[@mattson2001] dimers

Natural product modulators:

• Curcumin: Inhibits IKK activity and NF-κB[@mattson2001] nuclear translocation; poor bioavailability limits clinical utility
• Resveratrol: Activates SIRT1, which deacetylates p65 and suppresses NF-κB[@mattson2001] transcriptional activity
• Epigallocatechin gallate (EGCG): Suppresses NF-κB[@mattson2001] through multiple mechanisms

Indirect approaches:

• NSAIDs: Indirectly inhibit NF-κB[@mattson2001]; epidemiological data suggested reduced AD risk, but clinical trials have been mixed
• [GLP-1 receptor agonists](/therapeutics/glp-1-receptor-agonists): Suppress microglial NF-κB[@mattson2001] activation, showing neuroprotective effects in preclinical models
• Anti-TNF biologics: Block upstream NF-κB[@mattson2001] activation; retrospective studies suggest reduced dementia risk

Emerging Strategies

• Cell-type-specific delivery: Nanoparticles targeting [microglia](/cell-types/microglia) or [astrocytes](/cell-types/astrocytes) to spare neuronal NF-κB [@mattson2001]
• Pathway-selective inhibition: Targeting the non-canonical pathway or specific NF-κB[@mattson2001] dimers
• Epigenetic modulation: [HDAC](/entities/hdac-enzymes) inhibitors] can modulate NF-κB[@mattson2001] acetylation status
• Microglial phenotype switching: Promoting anti-inflammatory microglial states while preserving protective NF-κB[@mattson2001] in neurons

Interactions with Other Pathways

NF-κB[@mattson2001] serves as a signaling hub integrating multiple neurodegeneration-relevant pathways:

• [NLRP3 inflammasome](/mechanisms/nlrp3-inflammasome): NF-κB[@mattson2001] provides the priming signal (Signal 1) that upregulates [NLRP3](/mechanisms/nlrp3-inflammasome) and pro-IL-1β expression; bidirectional amplification loop
• [STING](/mechanisms/cgas-sting-neurodegeneration) pathway]: cGAS-STING activates NF-κB[@mattson2001] in parallel with IRF3, linking DNA damage sensing to inflammation
• JAK-STAT: Cytokine signaling integration; STAT3 cooperates with NF-κB[@mattson2001] in glial activation
• MAPK pathways: ERK, JNK, and p38 cross-talk with NF-κB[@mattson2001] at multiple levels
• [mTOR](/mechanisms/mtor-neurodegeneration): mTORC1 can activate IKK; NF-κB[@mattson2001] target genes include [mTOR](/mechanisms/mtor-neurodegeneration) regulators
• [Nrf2](/proteins/nrf2): Counterregulatory relationship — Nrf2 opposes NF-κB[@mattson2001]-driven oxidative stress; NF-κB[@mattson2001] can suppress Nrf2 expression
• [Tau](/proteins/tau) kinases: NF-κB[@mattson2001] activates [GSK-3β](/entities/gsk-3-beta) and [CDK5](/proteins/cdk5), promoting [tau](/proteins/tau) hyperphosphorylation]

NFκB1 as a Biomarker

Recent research has identified NFκB1 (p50/p105) as a potential common biomarker linking [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease) disease pathology ([Shi et al., 2025](https://pmc.ncbi.nlm.nih.gov/articles/PMC12089106/)):

• NFκB1 expression is altered in both AD and PD brain tissue
• Blood-based NFκB1-related inflammatory signatures correlate with disease progression
• Downstream NF-κB[@mattson2001] target cytokines (TNF-α, IL-6, IL-1β) in CSF and plasma track with disease severity
• These markers could serve for monitoring therapeutic response to anti-inflammatory interventions

Research Methods

Detection Techniques

| Method | Application | Resolution |
|--------|------------|------------|
| Immunohistochemistry | Nuclear p65 localization in tissue sections | Cellular |
| EMSA (Electrophoretic Mobility Shift Assay) | DNA-binding activity quantification | Molecular |
| Western blot | Protein levels, phosphorylation status | Molecular |
| NF-κB[@mattson2001] reporter assays | Transcriptional activity in live cells | Cellular |
| ChIP-seq | Genome-wide NF-κB[@mattson2001] binding site mapping | Genomic |
| qPCR of target genes | Downstream pathway activation | Molecular |
| Single-cell RNA-seq | Cell-type-specific NF-κB[@mattson2001] target expression | Single-cell |

Experimental Models

• [iPSC](/technologies/ipsc-disease-models)-derived neurons and [microglia: Patient-derived models for studying cell-type-specific NF-κB[@mattson2001]
• Transgenic AD mice ([APP](/entities/app-protein)/PS1, 5xFAD): Chronic NF-κB[@mattson2001] activation recapitulating human AD
• [α-synuclein](/proteins/alpha-synuclein) PFF models: Prion-like seeding of NF-κB[@mattson2001]-mediated inflammation
• Conditional NF-κB[@mattson2001] knockout mice: Cell-type-specific pathway deletion (CamKII-Cre for neurons, CX3CR1-Cre for [microglia](/cell-types/microglia)
• [Brain organoids](/technologies/brain-organoids): 3D models for studying glial-neuronal NF-κB[@mattson2001] cross-talk

Brain Atlas Resources

• Allen Human Brain Atlas: [NF-κB expression search](https://human.brain-map.org/microarray/search/show?search_term=NF-%CE%BAB)
• Allen Mouse Brain Atlas: [NF-κB search](https://mouse.brain-map.org/search/index.html?query=NF-%CE%BAB)
• Allen Cell Type Atlas: [Transcriptomic cell type reference](https://portal.brain-map.org/atlases-and-data/rnaseq)
• BrainSpan Developmental Transcriptome: [NF-κB developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=NF-%CE%BAB)

Pathway & Interaction Diagram

Interactive diagram showing NF-KB key relationships in the SciDEX knowledge graph (15 connections shown).

See Also

• [Index](/technologies/bci-index)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)

Background

The study of Nf Κb (Nuclear Factor Kappa B) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

[DOI:10.1172/JCI11916](https://doi.org/10.1172/JCI11916)
[DOI:10.1016/j.cell.2008.01.020](https://doi.org/10.1016/j.cell.2008.01.020)
[DOI:10.1146/annurev.immunol.18.1.621](https://doi.org/10.1146/annurev.immunol.18.1.621)
[DOI:10.1385/MN:31:1-3:175](https://doi.org/10.1385/MN:31:1-3:175)
[DOI:10.1002/(SICI](SICI])
[DOI:10.1016/j.nbd.2022.105642](https://doi.org/10.1016/j.nbd.2022.105642)

[Ju Hwang C, et al., The pivotal role of NF-kB in the pathogenesis and therapeutics of Alzheimer's Disease. Int J Mol Sci. 2022;23(16):8972. [PubMed (2022)](https://pubmed.ncbi.nlm.nih.gov/36012242/)

Jha NK, et al, NF-κB[1] in Alzheimer's Disease: friend or foe? Opposite functions in neurons and glial cells (2024)

[DOI:10.1038/s41598-024-65248-1](https://doi.org/10.1038/s41598-024-65248-1)
[DOI:10.3233/JAD-210111](https://doi.org/10.3233/JAD-210111) PMID: 31823227(https://pubmed.ncbi.nlm.nih.gov/31823227/)
[DOI:10.3390/biomedicines11092587](https://doi.org/10.3390/biomedicines11092587)

Shi Y, et al, NFκB1: a common biomarker linking Alzheimer's and Parkinson's Disease pathology (2025)

[DOI:10.1186/s40035-024-00401-4](https://doi.org/10.1186/s40035-024-00401-4)

Gupta SC, et al, NF-κB[1] in Alzheimer's Disease: role in pathogenesis and therapeutic potential (2023)

[DOI:10.1038/cdd.2011.71](https://doi.org/10.1038/cdd.2011.71)

Unknown, - Astrocytes (n.d.)

Unknown, - Microglia/cell-types/microglia (n.d.)

Unknown, - [TREM2 — [Triggering Receptor Expressed on Myeloid Cells 2] (n.d.)

Unknown, - tau protein]## External Links (n.d.)

-, NF-kB — NCBI Gene (n.d.)

-, NF-kB Signaling Pathway — KEGG (n.d.)

-, NF-kB — UniProt (NFKB1) (n.d.)

-, NF-kB — GeneCards (n.d.)

Pathway Diagram

The following diagram shows the key molecular relationships involving nf-kb discovered through SciDEX knowledge graph analysis: